Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.-MedSci.cn

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.

Timmerman, J; Lavie, D; Johnson, NA; Avigdor, A; Borchmann, P; Andreadis, C; Bazargan, A; Gregory, G; Keane, C; Inna, T; Vucinic, V; Zinzani, PL; Zhang, H; Pillai, P; Marinello, P; Herrera, AF

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.

科室

工具

服务